Lymph node enhancement at MRI with MnDPDP in primary hepatic carcinoma

Clinical Radiology

Volumn 56, Issue 1, 2001, Pages 67-71

  Burkill, Guy J C ^a   Mannion, Ethna M ^b   Healy, Jeremiah C ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Hepatocellular carcinoma; Liver; Lymph node; MnDPDP; MR imaging

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE; GADOTERIC ACID; MANGAFODIPIR; DIAGNOSTIC AGENT; DRUG DERIVATIVE; EDETIC ACID; MANGANESE; N,N' BIS(PYRIDOXAL 5 PHOSPHATE)ETHYLENEDIAMINE N,N' DIACETIC ACID; N,N'-BIS(PYRIDOXAL-5-PHOSPHATE)ETHYLENEDIAMINE-N,N'-DIACETIC ACID; PYRIDOXAL 5 PHOSPHATE;

ABDOMEN; ADULT; AGED; ARTICLE; CASE REPORT; CONTRAST ENHANCEMENT; CONTROLLED STUDY; EVALUATION; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CARCINOMA; LIVER CELL; LYMPH NODE HYPERPLASIA; LYMPH NODE METASTASIS; MALE; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDICAL RECORD; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIODIAGNOSIS; RETROSPECTIVE STUDY; SIGNAL PROCESSING; SPLEEN; LIVER CELL CARCINOMA; LIVER TUMOR; METASTASIS; METHODOLOGY;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; EDETIC ACID; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MANGANESE; PYRIDOXAL PHOSPHATE;

EID: 0034922196     PISSN: 00099260     EISSN: None     Source Type: Journal    
DOI: 10.1053/crad.2000.0605     Document Type: Article

References (13)

1. Mangafodipir trisodium, MnDPDP (Teslascan). A new organ-specific contrast agent for MR imaging
2. Preclinical evaluation of MnDPDP: New paramagnetic hepatobiliary contrast agent for MR imaging
3. Tissue distribution and general safety of MnDPDP in male beagle dogs, with and without total common bile duct obstruction
4. MnDPDP for MR imaging of the liver: Results from the European phase III studies
5. MR imaging properties and pharmacokinetics of MnDPDP in healthy volunteers
6. Comparison of manganese biodistribution and MR contrast enhancement in rats after intravenous injection of MnDPDP and MnCl2
7. Plasma pharmacokinetics, tissue distribution and excretion of MnDPDP in the rat and dog after intravenous administration
8. MnDPDP enhanced MR imaging of the liver: Correlation with surgical findings
9. Fibrolamellar carcinoma of the liver: A tumour of adolescents and young adults with distinctive clinico-pathological features
10. Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (MnDPDP)
11. Cirrhosis of the liver: MR imaging with mangafodipir trisodium (MnDPDP)
12. Results of an independent image evaluation of the European phase III studies
13. Tumoral portal vein thrombosis: Enhancement with MnDPDP